Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry

AmgenThe Amgen Foundation has announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program's inception in 1990. The Amgen Biotech Experience provides a real-world biotech lab experience to middle and high schools in Amgen's U.S. and United Kingdom (U.K.) communities and will engage more than 50,000 students this year. Education Development Center, Inc. (EDC), a global nonprofit organization that creates learning opportunities around the world, has also been named Program Office to oversee the program's implementation and facilitate its continued development.

Cutbacks in educational funding have led to limited resources for hands-on scientific experiences in many communities, and the National Academies' National Research Council has shown a significant connection between strong lab experiences and teachers' abilities to generate student interest in science. The Amgen Biotech Experience seeks to help make this connection in secondary school classrooms by introducing students to contemporary science techniques, including a robust, hands-on curriculum, research-grade equipment and comprehensive teacher training.

"By providing cutting-edge scientific experience today, students can begin to develop capabilities to make a powerful impact on society tomorrow," said Robert A. Bradway, chairman and chief executive officer of Amgen. "The Amgen Biotech Experience, designed in collaboration with educators and Amgen scientists, provides a rigorous real-world experience that helps open students' eyes to the world of biotechnology and scientific discovery."

In 2013, the Amgen Foundation will give more than $2.5 million in grants to community colleges, universities and nonprofit organizations that lead and support the Amgen Biotech Experience in different regions across the country where Amgen has a presence, including Southern and Northern California, Colorado, Washington, Rhode Island, Massachusetts, Puerto Rico and the U.K. The program will also be introduced in Washington, D.C., in 2014.

Since 1990, the Amgen Biotech Experience has engaged more than 300,000 students in learning molecular biology using relevant curricula, tools and techniques. Teachers are given a hands-on, inquiry-based, biology curriculum, in addition to a full suite of transportable, research-grade equipment and supplies, at no cost to the participating schools. Utilizing Nobel Prize-winning discoveries to prepare a recombinant DNA molecule that carries a gene for red fluorescent protein, students follow many of the steps biotechnology researchers use to produce medicines.

"I have been using the Amgen Biotech Experience in my classroom since 2008, and it is inspiring to see how eager the students are to learn these lab techniques. Several students have even told me they want to pursue a major in biology after they finish the course," said Amy Welch, a biology teacher at Brea Olinda High School in Brea, Calif. "As a teacher, my knowledge of biotechnology lab techniques has increased immensely since I first implemented the program and I feel that I am providing my students with skills that make them strong scientific thinkers. Given its genuine impact, I am so thankful to the Amgen Foundation for making this program possible."

Beginning this year, EDC will apply its deep experience in designing and delivering high-quality science education programs to establishing a Program Office for the Amgen Biotech Experience. Working closely with existing sites, EDC will build on the assets of the program and implement strategies to enrich the program, including the introduction of a new strengthened curriculum for this school year.

"EDC has a 50-year history of sharing the excitement of science learning with teachers and students," said Luther Luedtke, president and chief executive officer of EDC. "We are pleased to work alongside the Amgen Foundation to continue to make science compelling in the classroom and to encourage students to take up science-related careers."

For more information, please visit www.amgenbiotechexperience.com.

The Amgen Foundation supports numerous national and international organizations that strive to strengthen STEM (science, technology, engineering, mathematics) education and inspire students to pursue careers in science. To date, the Amgen Foundation has committed more than $80 million in science education funding to nonprofit organizations throughout the U.S., Puerto Rico and Europe.

About Amgen Foundation
The Amgen Foundation seeks to advance science education, improve patient access to quality care, and strengthen the communities where Amgen staff members live and work. To date, the Foundation has donated more than $200 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

About EDC
Education Development Center, Inc. (EDC) is a global nonprofit organization with headquarters located outside Boston, Massachusetts. EDC's mission is to create learning opportunities for people around the world, empowering them to pursue healthier and more productive lives. EDC works with public-sector and private partners, harnessing the power of people and systems to improve education, health promotion and care, workforce preparation, communications technologies and civic engagement. EDC manages 250 projects in 30 countries.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...